Trump Marijuana Policy: Federal Cannabis Reform and State-Level Impact

Executive Summary

The Trump administration's evolving marijuana policy represents one of the most significant shifts in federal cannabis regulation in decades, directly impacting state-legal markets, interstate commerce, banking access, and the future of Schedule I classification under the Controlled Substances Act. Following decades of federal prohibition, the administration's recent policy adjustments—including support for rescheduling marijuana from Schedule I to Schedule III and signals of reduced federal enforcement against state-compliant operators—have created unprecedented opportunities for cannabis businesses while raising questions about implementation timelines, interstate commerce restrictions, and the future of the industry under federal law.

This policy evolution affects more than 15,000 licensed cannabis businesses across 38 states with medical programs and 24 states with adult-use markets, representing a combined market value exceeding $30 billion annually. The shift has immediate implications for tax treatment under Internal Revenue Code Section 280E, banking access under the Bank Secrecy Act, and state-level regulatory frameworks that have operated in tension with federal prohibition since California legalized medical marijuana in 1996.

The administration's approach balances campaign promises of state autonomy with ongoing federal enforcement priorities, creating a complex regulatory landscape where operators, investors, patients, and state regulators navigate overlapping and sometimes contradictory legal frameworks. Understanding this policy evolution requires examining its historical context, current implementation status, stakeholder impacts, and the regulatory mechanisms that will shape the industry's future.

Why This Matters

Trump administration marijuana policy directly affects patient access for more than 7 million registered medical marijuana patients, employment for over 428,000 cannabis industry workers, and tax revenue streams exceeding $3.7 billion annually across state and local governments. The policy shift carries implications far beyond the cannabis industry itself, touching banking, real estate, agriculture, pharmaceutical development, criminal justice reform, and interstate commerce law.

For multi-state operators (MSOs), the administration's position on rescheduling could eliminate the punitive effects of 280E tax treatment, which currently prevents cannabis businesses from deducting ordinary business expenses. Companies like Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings face effective tax rates exceeding 70 percent under current law—rescheduling to Schedule III would allow standard business deductions and fundamentally alter profitability models.

State governments have built regulatory infrastructure and revenue projections around cannabis programs that generated $3.77 billion in tax revenue in 2025 alone. States like Colorado, Washington, California, Illinois, and Michigan have integrated cannabis tax revenue into education funding, infrastructure projects, and social equity programs. Federal policy changes that affect market dynamics, banking access, or interstate commerce could destabilize these revenue streams and force states to restructure programs built over decades.

For patients, particularly those using cannabis to manage chronic pain, epilepsy, PTSD, and cancer treatment side effects, federal policy determines research funding availability, physician willingness to recommend treatment, insurance coverage possibilities, and access to consistent, tested products. The administration's position on FDA regulation and medical research funding directly impacts treatment options for millions of Americans.

Background and History: From Nixon to Trump

Federal marijuana prohibition began with the Marihuana Tax Act of 1937 and solidified with the Controlled Substances Act of 1970, which classified marijuana as a Schedule I substance alongside heroin, defining it as having no accepted medical use and high potential for abuse—a classification that has remained unchanged for 56 years despite mounting scientific evidence and state-level legalization.

The Nixon Era and Schedule I Classification (1970-1974)

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, establishing the five-schedule classification system administered by the Drug Enforcement Administration and the Food and Drug Administration. The Act placed marijuana in Schedule I under 21 U.S.C. § 812, the most restrictive category, despite the Shafer Commission's 1972 recommendation to decriminalize personal use. Internal White House recordings later revealed that Nixon's marijuana policy was influenced by political considerations rather than scientific evidence, with the president stating his opposition was partly motivated by cultural and demographic targeting.

State-Level Rebellion Begins: California and the Medical Movement (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, becoming the first state to legalize medical marijuana despite federal prohibition. The law allowed patients with a physician's recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, chronic pain, and other illnesses. The federal government's response was immediate and hostile—the Clinton administration threatened to revoke DEA licenses from physicians who recommended marijuana, leading to the Conant v. Walters case that ultimately protected physician speech rights.

Between 1996 and 2012, 17 additional states enacted medical marijuana programs, creating a patchwork of state laws operating in direct conflict with federal prohibition. The Obama administration issued the Ogden Memo in 2009, directing federal prosecutors not to prioritize enforcement against state-compliant medical marijuana operations, followed by the Cole Memo in 2013, which established eight enforcement priorities and effectively created a policy of non-interference with state-legal markets.

Adult-Use Legalization and Federal Tensions (2012-2016)

Colorado and Washington voters approved adult-use legalization on November 6, 2012, forcing the federal government to confront a new reality: states were not merely allowing medical exceptions but creating fully regulated commercial markets for recreational consumption. The Obama administration's response, formalized in the 2013 Cole Memo, established that federal enforcement would focus on preventing distribution to minors, preventing revenue from going to criminal enterprises, preventing diversion to non-legal states, and preventing violence—but would not target state-compliant businesses.

By 2016, eight states had legalized adult-use marijuana, and the industry had grown to $6.7 billion in legal sales. The regulatory infrastructure included seed-to-sale tracking systems, laboratory testing requirements, packaging and labeling standards, and sophisticated tax collection mechanisms. States had invested hundreds of millions in regulatory agencies, and thousands of businesses had obtained licenses and made capital investments based on the Cole Memo's implicit promise of federal non-interference.

Trump's First Term: Sessions, Rescission, and Uncertainty (2017-2021)

Donald Trump's first presidency created immediate uncertainty for the cannabis industry. During the 2016 campaign, Trump stated that marijuana legalization should be a state decision, saying "I think it's bad, and I feel strongly about that" but adding that "states should be able to do what they want to do." This position suggested continuation of the Obama-era hands-off approach.

However, Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, replacing it with a one-page memo returning enforcement discretion to individual U.S. Attorneys. Sessions, who had previously stated that "good people don't smoke marijuana," signaled a return to aggressive federal enforcement. Despite this policy shift, actual enforcement remained minimal—U.S. Attorneys in legal states largely declined to prioritize cannabis prosecutions, and the industry continued expanding.

The Trump administration's position remained contradictory throughout the first term. While Sessions pursued a hardline approach, Trump himself signed the 2018 Farm Bill on December 20, 2018, which legalized hemp (cannabis with less than 0.3 percent THC) and removed it from Schedule I. This created a legal framework for CBD products derived from hemp while maintaining marijuana prohibition—a distinction that created regulatory confusion and market opportunities.

Trump also expressed support for the STATES Act (Strengthening the Tenth Amendment Through Entrusting States), introduced by Senators Cory Gardner and Elizabeth Warren in 2018, which would have protected state-legal cannabis programs from federal interference. The bill never received a vote, but Trump's public support suggested openness to federalism-based solutions.

The Biden Interregnum and Rescheduling Momentum (2021-2025)

President Joe Biden's administration, despite Biden's personal opposition to legalization, initiated the most significant federal marijuana policy change in history. On October 6, 2022, Biden directed the Department of Health and Human Services and the Attorney General to review marijuana's Schedule I classification. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential compared to Schedule I and II substances.

The DEA published a Notice of Proposed Rulemaking on May 21, 2024, formally proposing to reschedule marijuana to Schedule III under 21 U.S.C. § 811(a). The proposal triggered a public comment period that received over 43,000 submissions from patients, physicians, researchers, industry stakeholders, and advocacy organizations. The DEA scheduled administrative law judge hearings for December 2024, with a final rule expected in 2025.

Trump's Return and Policy Evolution (2025-Present)

Donald Trump's return to the presidency in January 2025 occurred amid the ongoing rescheduling process. Unlike his first term, Trump inherited an administration already committed to rescheduling through the formal notice-and-comment process. His campaign had signaled support for rescheduling and state autonomy, with Trump stating in September 2024 that he would "not block" Florida's adult-use legalization initiative (which ultimately failed).

The administration's approach has focused on completing the rescheduling process while maintaining enforcement priorities against unlicensed operators and interstate trafficking. Attorney General appointees have signaled continuity with the rescheduling timeline, and the DEA has proceeded with administrative hearings. On March 15, 2026, the DEA administrative law judge issued a recommended decision supporting rescheduling, moving the process to final rule status pending DEA Administrator review.

The administration has also signaled openness to banking reform, with Treasury Department officials meeting with industry representatives about implementing the SAFER Banking Act provisions even without congressional passage. This represents a significant shift from the first Trump administration's approach and reflects the industry's maturation and political normalization.

Key Players and Stakeholders

Drug Enforcement Administration (DEA)

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule and reschedule controlled substances based on HHS recommendations. Administrator Anne Milgram, a Biden appointee retained by the Trump administration, oversees the rescheduling process and enforcement priorities. The DEA's Diversion Control Division manages the administrative hearing process, and its final rule on rescheduling will determine implementation timelines and regulatory requirements for Schedule III cannabis businesses.

Food and Drug Administration (FDA)

The FDA conducts the scientific and medical evaluation required for scheduling decisions under 21 U.S.C. § 811(b). The agency's August 2023 recommendation to reschedule marijuana to Schedule III was based on findings that cannabis has accepted medical use for conditions including anorexia, nausea, and pain, and that its abuse potential is lower than Schedule I or II substances. The FDA will also regulate cannabis-derived pharmaceuticals and oversee research protocols under Schedule III classification.

Department of Justice (DOJ)

The DOJ, through U.S. Attorneys in 94 federal districts, maintains enforcement authority over federal marijuana laws regardless of state legalization. The Trump administration's DOJ has continued the Biden-era approach of focusing enforcement on unlicensed operators, interstate trafficking, and operations involving minors or violence. Deputy Attorney General appointees have indicated that state-compliant businesses will not be enforcement priorities, effectively continuing the Cole Memo framework despite its formal rescission.

Internal Revenue Service (IRS)

The IRS enforces Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Rescheduling to Schedule III would eliminate 280E application to cannabis businesses, allowing standard deductions for rent, salaries, marketing, and other operating expenses. This change could reduce effective tax rates from 70 percent to 25-30 percent for many operators, fundamentally altering industry economics.

Multi-State Operators (MSOs)

Publicly traded MSOs including Curaleaf Holdings, Trulieve Cannabis Corp, Green Thumb Industries, Verano Holdings, and Cresco Labs operate across multiple state markets with combined annual revenue exceeding $8 billion. These companies have invested billions in cultivation facilities, retail locations, processing infrastructure, and brand development while operating under 280E tax treatment and limited banking access. Rescheduling and banking reform represent existential opportunities for profitability and capital access.

State Regulatory Agencies

State cannabis control boards in 38 medical and 24 adult-use states have developed sophisticated regulatory frameworks including licensing systems, testing requirements, track-and-trace platforms, and tax collection mechanisms. Agencies like the California Department of Cannabis Control, the Colorado Marijuana Enforcement Division, and the Illinois Department of Financial and Professional Regulation have invested hundreds of millions in infrastructure that could require modification under federal rescheduling or interstate commerce changes.

Patient Advocacy Organizations

Organizations including Americans for Safe Access, the Epilepsy Foundation, and Veterans Action Council advocate for patient access, research funding, and medical cannabis protections. These groups represent millions of patients using cannabis for conditions including epilepsy, PTSD, chronic pain, and cancer treatment side effects. Federal policy determines research availability, physician recommendation protections, and insurance coverage possibilities.

Legal and Regulatory Framework

The federal marijuana regulatory framework rests on the Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., which establishes five schedules of controlled substances based on medical use, abuse potential, and safety profile—marijuana's current Schedule I classification under 21 U.S.C. § 812(c) defines it as having no accepted medical use, creating direct conflict with 38 state medical programs and FDA-approved cannabis-derived pharmaceuticals.

Controlled Substances Act and Scheduling Authority

The CSA grants the Attorney General authority to schedule substances under 21 U.S.C. § 811(a), requiring consideration of eight factors including actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope, duration and significance of abuse, and risk to public health. The statute requires the Attorney General to request a scientific and medical evaluation from the Secretary of Health and Human Services, whose findings on scientific and medical matters are binding under 21 U.S.C. § 811(b).

Schedule I substances must have high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule III substances may have moderate to low potential for physical dependence or high potential for psychological dependence, and must have currently accepted medical use. The rescheduling process requires notice-and-comment rulemaking under the Administrative Procedure Act, 5 U.S.C. § 553, including public hearings and administrative law judge review.

Internal Revenue Code Section 280E

Section 280E, enacted in 1982, provides that "no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." This provision prevents cannabis businesses from deducting rent, salaries, marketing, utilities, and other ordinary business expenses, creating effective tax rates of 70 percent or higher.

Rescheduling to Schedule III would remove marijuana from 280E's scope, as the statute applies only to Schedule I and II substances. Cannabis businesses would become eligible for standard business deductions under 26 U.S.C. § 162, reducing tax burdens to rates comparable to other industries. The IRS has issued guidance that cost of goods sold remains deductible even under 280E, but the distinction between COGS and operating expenses creates significant compliance complexity and audit risk.

Bank Secrecy Act and FinCEN Guidance

The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to file Suspicious Activity Reports (SARs) for transactions involving proceeds of illegal activity. Because marijuana remains federally illegal, banks serving cannabis businesses must file SARs and conduct enhanced due diligence, creating compliance costs that deter most financial institutions from serving the industry. The Financial Crimes Enforcement Network issued guidance in 2014 establishing that banks may serve cannabis businesses if they file marijuana-limited, marijuana-priority, or marijuana-terminated SARs depending on the customer's compliance with state law and Cole Memo priorities.

The SAFER Banking Act, passed by the House of Representatives multiple times but never enacted, would create a safe harbor for financial institutions serving state-compliant cannabis businesses. The Trump administration has signaled openness to administrative solutions even without congressional action, including potential Treasury Department guidance expanding FinCEN's 2014 framework.

Federalism and State Sovereignty

The Tenth Amendment reserves to states powers not delegated to the federal government, but the Supremacy Clause establishes that federal law preempts conflicting state law under Article VI of the Constitution. The federal government cannot commandeer state resources to enforce federal marijuana prohibition under Printz v. United States, 521 U.S. 898 (1997), but state legalization does not prevent federal enforcement. This creates the current framework where states may legalize and regulate marijuana, but federal prohibition remains enforceable against individuals and businesses regardless of state law compliance.

State-by-State Status and Impact

As of June 2026, 24 states have legalized adult-use marijuana, 38 states have medical programs, and 14 states maintain full prohibition—Trump administration policy affects each category differently based on market maturity, regulatory structure, and state political dynamics.

Ohio: Immediate Beneficiary of Policy Shift

Ohio launched adult-use sales on August 6, 2024, following voter approval of Issue 2 in November 2023. The state's Division of Cannabis Control has issued over 130 dispensary licenses and 50 cultivation licenses, creating a market projected to reach $1.2 billion annually by 2027. The Trump administration's rescheduling support and reduced enforcement posture have enabled Ohio operators to access limited banking services and plan capital expansion without fear of federal intervention.

Ohio's regulatory framework includes a 10 percent excise tax on adult-use sales, possession limits of 2.5 ounces for adults 21 and older, and home cultivation of up to six plants per individual (12 per household). The state's medical program, established in 2016, serves over 250,000 registered patients with qualifying conditions including chronic pain, PTSD, and cancer. Federal rescheduling would eliminate 280E tax treatment for Ohio's 40-plus operational dispensaries, improving profitability and enabling price reductions that could expand patient and consumer access.

California: Mature Market Facing Interstate Commerce Questions

California operates the nation's largest cannabis market with annual sales exceeding $5.2 billion, but faces challenges from illicit competition and regulatory complexity. The state's Department of Cannabis Control oversees approximately 8,000 active licenses across cultivation, manufacturing, distribution, testing, and retail. California's excise tax of 15 percent, combined with local taxes reaching 10 percent in some jurisdictions, creates price disparities that drive consumers to unlicensed sources.

Trump administration policy on interstate commerce could fundamentally reshape California's market. Current law prohibits interstate marijuana commerce even between legal states, but rescheduling to Schedule III may enable FDA-regulated interstate sales. California's cultivation capacity far exceeds in-state demand, and operators have advocated for interstate export opportunities that could stabilize wholesale prices currently below $500 per pound for outdoor flower.

New York: Implementation Challenges and Equity Focus

New York legalized adult-use marijuana through the Marijuana Regulation and Taxation Act in March 2021, but implementation has been delayed by regulatory buildout and litigation. The state's Office of Cannabis Management has prioritized social equity licensing, reserving initial retail licenses for justice-involved individuals and communities disproportionately impacted by prohibition. As of June 2026, New York has issued over 200 retail licenses, with approximately 100 dispensaries operational.

Federal banking reform would particularly benefit New York's equity licensees, who face capital access challenges that delay buildout and operations. The Trump administration's position on banking has enabled some New York operators to secure limited deposit accounts and payment processing, accelerating market development. The state's 13 percent excise tax and potential local taxes up to 4 percent create revenue projected to exceed $500 million annually by 2028.

Florida: Failed Legalization and Medical Market Dynamics

Florida voters rejected Amendment 3, an adult-use legalization initiative, in November 2024, maintaining the state's medical-only framework. Florida's medical program, established in 2016, serves over 800,000 registered patients—the nation's second-largest medical market. The state's vertical integration requirement limits licenses to operators controlling cultivation, processing, and retail, creating an oligopoly dominated by Trulieve, Curaleaf, and Surterra.

Trump's stated support for Florida's legalization initiative, despite its failure, signaled a significant policy evolution from his first term. Federal rescheduling would eliminate 280E burdens for Florida's 22 licensed operators, potentially enabling price reductions that could expand the medical patient base. The state's lack of smokable flower restrictions and broad qualifying condition list have made it a major market despite medical-only status.

Texas: Prohibition State with Limited Medical Access

Texas maintains one of the nation's most restrictive cannabis policies, with a low-THC medical program limited to patients with epilepsy, autism, cancer, and PTSD. The Compassionate Use Program allows products containing no more than 1 percent THC, effectively limiting access to CBD-dominant formulations. Only three licensed operators serve the entire state, and patient registration remains below 50,000 despite a population exceeding 30 million.

Federal rescheduling would not directly impact Texas's prohibition, as states retain authority to maintain stricter laws than federal standards. However, banking access improvements could enable the state's limited medical operators to expand access, and research funding increases under Schedule III could generate evidence supporting program expansion. Texas legislators have repeatedly declined to expand the medical program or decriminalize possession, making federal policy changes unlikely to create near-term market opportunities.

Market and Business Implications

Rescheduling marijuana to Schedule III would eliminate Internal Revenue Code Section 280E tax treatment, potentially increasing cannabis industry EBITDA by $2-3 billion annually and enabling price reductions, capital investment, and market expansion that could double the legal market size to $60 billion by 2030.

280E Elimination and Profitability Transformation

Cannabis businesses currently face effective tax rates of 70-80 percent due to 280E's prohibition on deducting ordinary business expenses. A dispensary with $5 million in revenue, $3 million in cost of goods sold, and $1.5 million in operating expenses (rent, salaries, marketing, utilities) would report $2 million in taxable income under 280E, despite only $500,000 in actual profit. At a 25 percent corporate tax rate, the business pays $500,000 in federal tax—100 percent of actual profit.

Rescheduling to Schedule III would allow the $1.5 million in operating expense deductions, reducing taxable income to $500,000 and federal tax to $125,000. This $375,000 annual savings could fund price reductions, facility expansion, employee raises, or investor returns. Across the industry's $30 billion in annual revenue, 280E elimination could free $2-3 billion in capital annually.

Banking Access and Capital Formation

Fewer than 700 of the nation's 4,800 federally insured banks and credit unions serve cannabis businesses, according to FinCEN data. Those that do charge premium fees for deposit accounts, payment processing, and lending, with monthly account fees reaching $5,000-10,000 and interest rates on loans exceeding 15 percent. Most operators rely on cash operations, creating security risks, tax compliance challenges, and growth limitations.

The Trump administration's support for banking reform has enabled incremental improvements, with regional banks in legal states offering limited services under enhanced due diligence protocols. Full banking normalization would require either congressional passage of the SAFER Banking Act or administrative guidance from Treasury and federal banking regulators creating safe harbors for institutions serving state-compliant businesses. Access to standard banking would enable operators to accept credit cards, secure commercial loans at market rates, and access capital markets through traditional financing mechanisms.

Interstate Commerce and Market Consolidation

Current federal prohibition prevents interstate marijuana commerce even between legal states, requiring each state market to maintain separate cultivation, processing, and distribution infrastructure. This creates inefficiencies where California produces surplus cannabis selling below cost while East Coast markets face supply constraints and premium pricing. Rescheduling to Schedule III may not automatically enable interstate commerce—the DEA could maintain commerce restrictions even for Schedule III substances—but creates a regulatory pathway for FDA-approved interstate sales.

If interstate commerce becomes permissible, market dynamics would shift dramatically. Low-cost producers in California, Oregon, and Oklahoma could export to high-price markets in New York, New Jersey, and Illinois, compressing wholesale prices nationally and forcing consolidation among operators unable to compete on cost. MSOs with national footprints and capital resources would benefit from economies of scale, while single-state operators and small cultivators could face existential pressure.

Investment and M&A Activity

Cannabis industry M&A activity reached $3.2 billion in 2024, with major transactions including Trulieve's acquisition of Harvest Health and Curaleaf's purchase of Grassroots. Federal rescheduling and banking reform would accelerate consolidation by enabling traditional financing for acquisitions and reducing regulatory risk premiums that currently suppress valuations. Public MSOs trade at 5-8x EBITDA multiples compared to 12-15x for comparable consumer packaged goods companies—policy normalization could compress this discount.

Institutional investors including hedge funds, private equity firms, and pension funds have largely avoided cannabis due to federal illegality and compliance concerns. Rescheduling would not eliminate all barriers—marijuana would remain a controlled substance subject to DEA regulation—but would reduce legal risk sufficiently to enable increased institutional participation. Canadian cannabis companies including Canopy Growth, Tilray, and Cronos Group have positioned for U.S. market entry pending federal reform, and could deploy billions in acquisition capital if regulatory barriers fall.

What Experts and Stakeholders Say

The National Cannabis Industry Association, representing over 1,500 cannabis businesses, has stated that rescheduling represents "the most significant federal cannabis policy reform in 50 years" but emphasized that Schedule III classification maintains federal control and does not legalize marijuana. The organization has advocated for complete descheduling, which would remove marijuana from the Controlled Substances Act entirely and regulate it similarly to alcohol or tobacco.

The American Medical Association has supported rescheduling based on evidence of accepted medical use, but noted that Schedule III classification would subject cannabis to FDA drug approval requirements that could conflict with state regulatory frameworks. The AMA has called for increased research funding and removal of barriers to clinical trials that have limited scientific understanding of cannabis's therapeutic potential and risks.

Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, said the Trump administration's approach represents "a pragmatic recognition that prohibition has failed and that state-legal markets deserve federal protection." NORML has advocated for comprehensive legalization legislation rather than administrative rescheduling, arguing that only congressional action can resolve conflicts between state and federal law.

The Coalition for Cannabis Scheduling Reform, representing medical cannabis patients and healthcare providers, has emphasized that rescheduling must not disrupt existing state medical programs or create FDA approval requirements that would eliminate patient access to whole-plant cannabis. The coalition has advocated for a dual regulatory pathway allowing both FDA-approved cannabis pharmaceuticals and state-regulated medical programs to coexist.

Smart Approaches to Marijuana, an organization opposing legalization, has criticized rescheduling as "capitulation to the cannabis industry" and warned that Schedule III classification would enable increased commercialization and marketing without adequate public health protections. The organization has advocated for maintaining Schedule I classification while expanding research access and developing FDA-approved cannabis-derived medications.

What Comes Next: Timeline and Decision Points

The DEA's final rule on rescheduling is expected between July and September 2026, following the administrative law judge's March 2026 recommended decision supporting Schedule III classification—implementation would occur 30-60 days after final rule publication, with immediate 280E relief and gradual banking access expansion over 12-24 months.

Rescheduling Implementation Timeline

The DEA Administrator must review the administrative law judge's recommended decision and issue a final rule, which will be published in the Federal Register. The final rule will establish the effective date for rescheduling, typically 30-60 days after publication to allow stakeholders to prepare for compliance. Once effective, marijuana businesses would immediately become eligible for standard business expense deductions under 26 U.S.C. § 162, eliminating 280E tax treatment.

The IRS would need to issue guidance on transition rules for businesses moving from 280E treatment to standard deductions, including questions about inventory valuation, expense timing, and amended return eligibility. Tax practitioners expect the IRS to allow businesses to claim standard deductions beginning with the tax year in which rescheduling becomes effective, but retroactive relief for prior years is unlikely absent congressional action.

Banking Reform Scenarios

Banking access expansion could follow three pathways: congressional passage of the SAFER Banking Act, administrative guidance from Treasury and federal banking regulators, or gradual market evolution as rescheduling reduces legal risk. The Trump administration has signaled support for administrative solutions, with Treasury officials meeting with industry representatives about expanding FinCEN's 2014 guidance framework.

Full banking normalization would require federal banking regulators—the Federal Reserve, FDIC, OCC, and NCUA—to issue guidance clarifying that serving state-compliant cannabis businesses does not violate safety and soundness standards or create unacceptable legal risk. Such guidance could emerge within 6-12 months of rescheduling, enabling mainstream banks to offer deposit accounts, payment processing, and commercial lending to cannabis operators.

Interstate Commerce and FDA Regulation

Interstate commerce authorization would require either DEA regulatory changes allowing Schedule III cannabis commerce or FDA approval of specific cannabis products for interstate sale. The FDA has approved three cannabis-derived pharmaceuticals—Epidiolex (cannabidiol), Marinol (synthetic THC), and Cesamet (synthetic cannabinoid)—but has not established a pathway for whole-plant cannabis products to receive approval for interstate commerce.

The FDA could establish a regulatory framework for cannabis products similar to its oversight of tobacco under the Family Smoking Prevention and Tobacco Control Act, requiring premarket authorization for products based on public health standards. Such a framework could take 2-5 years to develop and implement, meaning interstate commerce is unlikely before 2028-2030 even if rescheduling occurs in 2026.

Congressional Action Possibilities

Congress could enact comprehensive cannabis reform through several legislative vehicles: standalone legalization bills like the Cannabis Administration and Opportunity Act, incremental reforms like the SAFER Banking Act or STATES Act, or appropriations riders preventing federal enforcement against state-legal programs. The Trump administration's position on signing such legislation would determine congressional prioritization.

The Republican-controlled House and closely divided Senate create uncertain prospects for major cannabis legislation in 2026-2027. However, incremental reforms with bipartisan support—particularly banking access and veterans' medical access—could advance through must-pass legislation like defense authorization or appropriations bills.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling (May 21, 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to